Regulators Still To Get To Grips With Neurodegenerative Outcome Measures

 
• By Francesca Bruce

Outcomes measures in the neurodegenerative disease space are not yet well understood by regulators, according to Amylyx, which recently received a negative opinion from the EMA for its amyotrophic lateral sclerosis drug, Albrioza.

Path in forest
Regulators approach new outcome measures in neurodegenerative diseases • Source: Shutterstock

More from Europe

More from Geography